Aidoc vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aidoc is an AI radiology platform with FDA-cleared algorithms that detect and flag critical findings in medical scans, helping radiologists prioritize urgent cases.
About
Aidoc is an Israeli-American AI medical imaging company founded in 2016 that has built a comprehensive AI radiology platform with the largest portfolio of FDA-cleared imaging algorithms in the market. The platform integrates with radiology workflow systems to automatically analyze incoming scans, detect critical findings across multiple conditions, and prioritize worklists so radiologists review the most urgent cases first rather than working strictly in order of arrival. Aidoc's algorithms cover a broad range of conditions across multiple anatomical regions including intracranial hemorrhage, pulmonary embolism, incidental pulmonary nodules, and spine fractures. The company raised over $140M and is deployed at over 1,000 healthcare sites worldwide. Aidoc's aiOS platform enables third-party AI algorithms to run alongside its own models, creating an open ecosystem for AI in radiology. The company serves radiology departments seeking to improve throughput, reduce missed findings, and support radiologists managing increasing imaging volumes. Aidoc positions its platform as an AI operating system for radiology rather than a collection of point solutions, enabling comprehensive AI coverage across an entire radiology practice.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.